文献速递糖尿病

非诺贝特使用与2型糖尿病威胁视力视网膜病变的关联:英国真实世界证据

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-07

本研究基于英国初级保健数据库,采用倾向评分匹配的新使用者比较效果研究,纳入16,337名非诺贝特新使用者与25,764名匹配的他汀使用者,随访至12年。结果显示非诺贝特使用与威胁视力糖尿病视网膜病变(STDR)风险降低相关(ITT aHR 0.87,95%CI 0.82-0.93;PP aHR 0.80,95%CI 0.74-0.87)。

要点

  • 非诺贝特使用与他汀相比与STDR风险降低相关。
  • 保护效应在年龄、性别、族裔和血脂亚组中一致,但南亚裔中未观察到。
  • 提示非诺贝特或可考虑作为2型糖尿病患者的DR预防治疗。

核心结论

  • 在真实世界临床实践中,非诺贝特使用与2型糖尿病患者STDR风险降低相关。
  • 这些发现提示非诺贝特或可考虑作为2型糖尿病患者的DR预防治疗。

研究设计与样本

  • 倾向评分匹配的现患新使用者比较效果试验模拟研究。
  • 纳入年龄≥18岁的2型糖尿病成人,数据来自英国临床实践研究数据链(2000年1月1日至2022年6月30日)。
  • 非诺贝特新使用者16,337名与匹配的他汀使用者25,764名,随访至12年。

主要发现

  • 与非诺贝特使用相关的STDR风险降低:ITT aHR 0.87(95%CI 0.82-0.93),PP aHR 0.80(95%CI 0.74-0.87)。
  • 结果在敏感性分析和基于年龄、性别、族裔、血脂水平的亚组中一致。
  • 南亚裔中未观察到保护效应。

关键数值与推荐

  • 主要结局为 incident STDR。
  • 采用竞争风险Cox比例风险回归模型估计粗风险比和调整风险比(aHR)。

临床怎么用

  • 对于2型糖尿病患者,非诺贝特使用可能与较低的STDR风险相关,可考虑作为DR预防治疗选项。
  • 南亚裔患者中保护效应未观察到,临床决策需个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Half of individuals with type 2 diabetes (T2D) also experience dyslipidaemia. In a phase IV clinical trial, fenofibrate was shown to reduce the risk of referable diabetic retinopathy (DR) comparing to placebo in people with background diabetic retinopathy (BDR). We aimed to generate comprehensive real-world evidence on the effects of fenofibrate on the risk of sight-threatening diabetic retinopathy (STDR) in individuals with T2D, compared with statins. METHODS: This propensity score-matched, prevalent new-user comparative effectiveness trial emulation study included adults (≥18 years) with T2D, receiving either statins or fenofibrate, as recorded in Clinical Practice Research Datalink (a UK primary care database) from 1 January 2000 to 30 June 2022. The primary outcome was incident STDR. After propensity score matching, competing risk Cox proportional hazard regression models were used to estimate the crude and adjusted hazard ratios (aHR) in both intention-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: Data from 16,337 fenofibrate new users and their matched 25,764 statin users were included in this study. Participants were followed up for up to 12 years. Fenofibrate use was associated with a reduced risk of developing STDR (aHR: ITT 0.87, 95% CI 0.82-0.93; PP 0.80, 0.74-0.87) in comparison with the statin group. The results were consistent across sensitivity analysis and subgroups based on age, sex, ethnicity, and lipid levels. However, the protective effect was not observed in South Asians. CONCLUSIONS: Fenofibrate use was associated with a reduced risk of STDR in individuals with T2D in the real-world clinical practice. These fundings suggest that fenofibrate could be considered as a DR preventive therapy for individuals with T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tan L, Cooper JM, Gokhale K, et al. Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. J Clin Endocrinol Metab. 2026. PMID: 42702803. doi:10.1210/clinem/dgag367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。